314 related articles for article (PubMed ID: 23384753)
1. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis.
Malagón T; Joumier V; Boily MC; Van de Velde N; Drolet M; Brisson M
Vaccine; 2013 Mar; 31(13):1740-7. PubMed ID: 23384753
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
3. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccine and sexual behavior among adolescent and young women.
Liddon NC; Leichliter JS; Markowitz LE
Am J Prev Med; 2012 Jan; 42(1):44-52. PubMed ID: 22176845
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model.
Shafer LA; Jeffrey I; Elias B; Shearer B; Canfell K; Kliewer E
Vaccine; 2013 Oct; 31(42):4848-55. PubMed ID: 23933332
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
8. Sexual behavior, use of contraceptive methods and risk factors for HPV infections of students living in central Italy: implications for vaccination strategies.
Boccalini S; Tiscione E; Bechini A; Levi M; Mencacci M; Petrucci F; Bani Assad G; Santini MG; Bonanni P
J Prev Med Hyg; 2012 Mar; 53(1):24-9. PubMed ID: 22803316
[TBL] [Abstract][Full Text] [Related]
9. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
10. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
11. Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era.
Malagón T; Drolet M; Boily MC; Laprise JF; Brisson M
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):276-85. PubMed ID: 25380735
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
14. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
15. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
17. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
18. Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland.
Riesen M; Garcia V; Low N; Althaus CL
Vaccine; 2017 Dec; 35(52):7312-7321. PubMed ID: 29126806
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine acceptability among young adult men.
Gerend MA; Barley J
Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
[TBL] [Abstract][Full Text] [Related]
20. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]